Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis

2013 ◽  
Vol 51 (05) ◽  
pp. 407-415 ◽  
Author(s):  
Chenhui Deng ◽  
Taotao Liu ◽  
Tianyan Zhou ◽  
Hua Lu ◽  
Daohai Cheng ◽  
...  
Keyword(s):  
Initial Dosage ◽  
Population Pharmacokinetic Analysis ◽  
Adult Patients ◽  
Pharmacokinetic Analysis ◽  
Population Pharmacokinetic ◽  
Chinese Adult ◽  
Dosage Regimens

Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies

2004 ◽  
Vol 55 (3) ◽  
pp. 237-243 ◽  
Author(s):  
Xueyu Chen ◽  
Robert R. Bies ◽  
Ramesh K. Ramanathan ◽  
Eleanor G. Zuhowski ◽  
Donald L. Trump ◽  
...  
Keyword(s):  
Population Pharmacokinetic Analysis ◽  
Adult Patients ◽  
Pharmacokinetic Analysis ◽  
Population Pharmacokinetic ◽  
Advanced Malignancies

scholarly journals Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections

2021 ◽  
Author(s):  
Pier Giorgio Cojutti ◽  
Matteo Rinaldi ◽  
Eleonora Zamparini ◽  
Nicolò Rossi ◽  
Sara Tedeschi ◽  
...  
Keyword(s):  
Plasma Concentrations ◽  
Compartment Model ◽  
Population Pharmacokinetic Analysis ◽  
Term Treatment ◽  
Adult Patients ◽  
Pharmacokinetic Analysis ◽  
Population Pharmacokinetic ◽  
Long Term Treatment ◽  
Prosthetic Joint Infections ◽  
Dosing Regimens

Background: Dalbavancin is gaining interest in the treatment of complex osteoarticular (OA) infections. Objective: To conduct a population pharmacokinetic analysis of dalbavancin in a prospective cohort of adult patients with Gram-positive OA infections and to identify optimal dosing regimens for long term-treatment. Methods: Non-linear mixed-effects modelling was performed with Monolix. Monte Carlo simulations were performed with six dalbavancin regimens (1500mg at day 1; 1000mg at day 1 plus 500mg at day 8; 1500mg at day1 and 8; 1500mg at day1 and 8 plus 500, 1000 or 1500mg at day 36) to assess the PTA of three pharmacodynamic target of fAUC24h/MIC against S. aureus (>27.1, 53.3 and 111.1). Cumulative fraction of response (CFR) was calculated against MIC distribution of both MRSA and MSSA as well. Desirable PTAs and CFRs were ≥90%. Results: Fifteen patients provided 120 plasma concentrations. Most (73.3%) had prosthetic joint infections. Clinical cure rate was 87%. A two-compartment model with linear elimination well described the data. No covariate was retained in the final model. Pharmacokinetic dalbavancin estimates were 0.106L/h for CL and 36.4L for Vss. The tested dosing regimens granted desirable CFRs against S. aureus at the most effective PK/PD target for a period ranging 3-to-9 weeks. Conclusion: Giving a two 1500mg dosing regimen of dalbavancin one week apart may ensure efficacy against both MSSA and MRSA up to 5 weeks in patients with OA infections. Clinical assessment at that time may allow for considering whether or not an additional dose should be administered for prolonging effective treatment.

scholarly journals Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors

2012 ◽  
Vol 70 (1) ◽  
pp. 201-205 ◽  
Author(s):  
Abdulateef O. Aregbe ◽  
Eric A. Sherer ◽  
Merrill J. Egorin ◽  
Howard I. Scher ◽  
David B. Solit ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Population Pharmacokinetic Analysis ◽  
Adult Patients ◽  
Pharmacokinetic Analysis ◽  
Population Pharmacokinetic
Sign in / Sign up

Export Citation Format

Share Document